Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlook

Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets - Novo Nordisk (NYSE:NVO)

Earlier on Wednesday, Denmark’s most valuable company, Novo Nordisk A/S (NYSE:NVO), reported second-quarter earnings that missed the analyst consensus. In its quarterly earnings presentation, Novo Nordisk said that in January 2024, it submitted the results from Wegovy STEP HFpEF trials for regulatory review in the US and EU. Based on interactions with the FDA, the company has decided to withdraw the file. It expects to resubmit the file at the b…

Danish weight-loss drug maker Novo Nordisk posts slight profit rise

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday a slight increase in net profit for the second quarter.

Ozempic maker Novo Nordisk misses profit estimates as it builds out capacity

Novo Nordisk, Europe’s largest company by market cap thanks to its wildly popular weight-loss drugs, managed just a small increase in second-quarter profits as it builds out the capacity to make the products.

Obesity drugmaker Novo Nordisk misses Q2 profit forecast

Novo Nordisk on Wednesday posted second-quarter operating profit below expectations, raised its 2024 sales forecast but trimmed profit outlook, as competition from Eli Lilly in the booming weight-loss drug market intensifies.

Obesity drugmaker Novo Nordisk misses Q2 profit forecast

Novo Nordisk has today posted second-quarter operating profit below expectations, raised its 2024 sales forecast but cut profit outlook, as competition from Eli Lilly in the booming weight-loss drug market intensifies.

Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlook

Novo Nordisk on Wednesday announced its second quarter earnings for 2024.